Angiotensin 1/2 (5-7): A Potent Vasoconstrictor Peptide for Renin-Angiotensin System Research

Executive Summary: Angiotensin 1/2 (5-7) is a biologically active peptide with the sequence H2N-Ile-His-Pro-OH, derived from angiotensinogen via the renin-angiotensin system (RAS) (APExBIO product page). It functions as a vasoconstrictor, elevating blood pressure by acting on vascular smooth muscle cells (Oliveira et al. 2025). The peptide shows high solubility in DMSO (≥36.5 mg/mL), ethanol (≥50 mg/mL), and water (≥50 mg/mL) and is quality-controlled via HPLC and mass spectrometry (HPLC purity 98.36%). Recent research implicates angiotensin peptides, including N-terminal deletions like (5-7), in enhancing SARS-CoV-2 spike protein binding to cellular receptors, thereby expanding their relevance to viral pathogenesis studies. APExBIO supplies the product under SKU A1049, with detailed workflow and storage guidance for reproducible research.

Biological Rationale

Angiotensin 1/2 (5-7) is a tripeptide produced by N-terminal cleavage of longer angiotensin peptides, part of the RAS pathway critical for cardiovascular regulation (Oliveira et al. 2025). The RAS begins with hepatic synthesis of angiotensinogen, which is converted to angiotensin I (1–10) by renin from the kidney. Angiotensin I is further processed to angiotensin II (1–8), an established vasoconstrictor. Sequential cleavages yield shorter fragments such as angiotensin (1–7), (2–7), and (5–7), each with distinct biological activities. Angiotensin 1/2 (5-7) acts as a potent vasoconstrictor and dipsogen, influencing both vascular tone and fluid intake. It is a critical molecular tool for dissecting blood pressure regulation, hypertension, and emerging roles in viral entry mechanisms (compare: advanced peptide signaling—this article quantifies viral interaction relevance).

Mechanism of Action of Angiotensin 1/2 (5-7)

The peptide H2N-Ile-His-Pro-OH (Angiotensin 1/2 (5-7)) exerts its effects by binding to angiotensin receptors on vascular smooth muscle cells. This triggers intracellular signaling cascades, resulting in calcium influx and muscle contraction, leading to vasoconstriction and increased systemic blood pressure (Oliveira et al. 2025). Short angiotensin fragments such as (5-7) have been shown to enhance the binding of the SARS-CoV-2 spike protein to AXL, a secondary viral receptor, with a potency exceeding that of the full-length angiotensin II peptide. This enhancement is measurable as a >2-fold increase in spike–AXL interaction in antibody binding assays (Figure 2). The specificity of (5-7) for AXL over ACE2 or NRP1 suggests unique conformational or charge-related interactions that can be leveraged for mechanistic studies. These properties make Angiotensin 1/2 (5-7) uniquely suited for both cardiovascular and viral pathogenesis research (see: emerging molecular biology—this article highlights new viral entry mechanisms).

Evidence & Benchmarks

• Angiotensin 1/2 (5-7) is generated by N-terminal cleavage of angiotensin (1–7), confirmed by mass spectrometry and peptide mapping (Oliveira et al. 2025).
• The peptide sequence H2N-Ile-His-Pro-OH is validated with a molecular weight of 365.43 Da and formula C₁₇H₂₇N₅O₄ (APExBIO product specification: SKU A1049).
• Shorter angiotensin peptides, including (5-7), enhance SARS-CoV-2 spike protein binding to AXL by up to 2.7-fold relative to control in antibody-based binding assays (Figure 2, Table 1).
• Angiotensin 1/2 (5-7) demonstrates solubility ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, and ≥50 mg/mL in water at room temperature (APExBIO datasheet: see storage/solubility).
• HPLC purity is measured at 98.36%, and peptide identity is confirmed by MS; shipped on blue ice to maintain stability (APExBIO, SKU A1049).
• Angiotensin 1/2 (5-7) acts as a potent vasoconstrictor in vitro and in vivo, raising arterial pressure in animal models (Oliveira et al. 2025).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is used in research to:

• Model acute and chronic blood pressure regulation in hypertensive animal models.
• Investigate RAS modulation and downstream signaling effects in cell systems.
• Probe the molecular mechanisms of SARS-CoV-2 entry, especially AXL-mediated pathways (Oliveira et al. 2025).
• Test dipsogenic responses in behavioral pharmacology assays.
• Serve as a benchmark control in solubility, purity, and activity assays for peptide workflow validation (compare: cell viability guidance—this article focuses on viral and cardiovascular endpoints).

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (5-7) is not a direct therapeutic for hypertension; it is a research tool only.
• It does not activate all angiotensin receptors equally; specificity varies by receptor subtype and cell context.
• Long-term storage of solutions is not recommended; peptide degradation can occur above -20°C or with repeated freeze-thaw cycles (APExBIO guidance).
• Not all observed vasoconstrictor effects in vitro translate directly to in vivo cardiovascular or renal outcomes.
• Enhancement of SARS-CoV-2 spike–AXL binding by angiotensin fragments is context-dependent and should not be generalized to all viral entry models.

Workflow Integration & Parameters

APExBIO provides Angiotensin 1/2 (5-7) (SKU A1049) as a solid, shipped on blue ice for stability during transport. For laboratory use, stock solutions can be prepared at ≥36.5 mg/mL in DMSO, or ≥50 mg/mL in ethanol or water. Solutions should be prepared fresh and used promptly; aliquot and store at -20°C for short-term needs. The peptide is compatible with standard cell culture media and in vivo dosing vehicles, pending sterile filtration. Quality control includes HPLC (98.36% purity) and mass spectrometry identity confirmation. Refer to this article for a focus on hypertension workflows—this review broadens scope to viral studies and peptide solubility.

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a validated tool for dissecting RAS signaling, blood pressure regulation, and emerging viral entry mechanisms. The peptide's high solubility, purity, and reliable vasoconstrictor activity make it indispensable for cardiovascular, renal, and viral pathogenesis research. Ongoing studies continue to clarify the unique roles of short angiotensin fragments in both physiological and pathophysiological contexts. For detailed protocols and ordering, see the Angiotensin 1/2 (5-7) product page from APExBIO.